Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

Company profile
Ticker
CLBS
Exchange
Website
CEO
David Mazzo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CORNICHE GROUP INC /DE, NeoStem, Inc., PHASE III MEDICAL INC/DE
SEC CIK
Corporate docs
Subsidiaries
Amorcyte, LLC • Athelos Corporation • NeoStem Oncology, LLC • As of December 31, 2019, Becton Dickinson's ownership interest in Athelos Corporation ...
IRS number
222343568
CLBS stock data
News

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
10 Aug 22
Caladrius Biosciences' Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement With Roche To Evaluate CEND-1 In Combination With Immunotherapy To Treat Pancreatic Cancer
10 Aug 22
Caladrius Biosciences Q2 EPS $(0.11) Misses $(0.10) Estimate
4 Aug 22
Earnings Scheduled For August 4, 2022
4 Aug 22
Earnings Outlook For Caladrius Biosciences
3 Aug 22
Press releases
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANT
4 Aug 22
CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS
3 Aug 22
Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
28 Jul 22
Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group
9 Jun 22
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates PSB, GTYH, CLBS, FSI
25 May 22
Investment data
Securities sold
Number of investors
Calendar
4 Aug 22
18 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.35M | 33.35M | 33.35M | 33.35M | 33.35M | 33.35M |
Cash burn (monthly) | (no burn) | (no burn) | 2.24M | 2.27M | 1.69M | 1.7M |
Cash used (since last report) | n/a | n/a | 3.69M | 3.74M | 2.78M | 2.79M |
Cash remaining | n/a | n/a | 29.66M | 29.61M | 30.57M | 30.55M |
Runway (months of cash) | n/a | n/a | 13.2 | 13.0 | 18.1 | 18.0 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Jan 22 | Todd C Girolamo | Common Stock | Payment of exercise | Dispose F | No | No | 0.8204 | 2,158 | 1.77K | 160,827 |
14 Jan 22 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 0.8204 | 6,611 | 5.42K | 631,065 |
13 Jan 22 | Todd C Girolamo | Common Stock | Payment of exercise | Dispose F | No | No | 0.8063 | 2,563 | 2.07K | 162,985 |
13 Jan 22 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 0.8063 | 6,471 | 5.22K | 637,676 |
10 Jan 22 | Brown Gregory B | Common Stock | Grant | Acquire A | No | No | 0 | 65,430 | 0 | 149,040 |
10 Jan 22 | Michael H. Davidson | Common Stock | Grant | Acquire A | No | No | 0 | 65,430 | 0 | 209,753 |
10 Jan 22 | Schwalm Cynthia | Common Stock | Grant | Acquire A | No | No | 0 | 65,430 | 0 | 145,847 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Competition
Nektar Therapeutics • BioCardia • Sangamo Therapeutics • Athersys • Cellular Biomedicine • VistaGen Therapeutics • Selecta Biosciences • BiostageRisks
- We currently do not meet the continued listing standards of the Nasdaq Capital Market, which require a minimum closing bid price of $1.00 per share. Our failure to meet Nasdaq’s continued listing standards could result in the delisting of our common stock, negatively impact the price of our common stock and negatively impact our ability to raise additional capital.
- Our merger with Cend may not be consummated or may not deliver the anticipated benefits we expect.
- Our net cash may be less than the required amount at the closing of the Merger, which would result in our stockholders owning a smaller percentage of the combined organization and could even result in the termination of the Merger Agreement.
- Failure to complete the Merger may result in us paying a termination fee or expenses to Cend and could harm the price of our common stock and our future business and operations.
- The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.
- The market price of our common stock following the Merger may decline as a result of the Merger.
- Our stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger.
- Our stockholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined organization following the completion of the Merger as compared to their current ownership and voting interests.
- During the pendency of the Merger, we may not be able to enter into a business combination with another party at a favorable price because of restrictions in the Merger Agreement, which could adversely affect our respective businesses.
- Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement.
- If the conditions of the Merger are not met, the Merger will not occur.
Management Discussion
- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- We are a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. We are developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Our technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.
- Our leadership team has decades of collective biopharmaceutical product development experience in a variety of therapeutic categories, including cardiovascular and oncology. Our goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. Our current product candidates include:
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
ASC, case, catheter, contrast, corroborate, cumulative, formal, impairment, oncology, perspective, suspension, typically
Financial reports
Current reports
8-K
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
5 Aug 22
8-K
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
23 May 22
8-K
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
4 May 22
8-K
Caladrius Biosciences and Cend Therapeutics Announce
27 Apr 22
8-K
Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
22 Mar 22
8-K
Departure of Directors or Certain Officers
25 Feb 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Feb 22
8-K
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results
4 Nov 21
8-K
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
5 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 21
Registration and prospectus
425
Business combination disclosure
15 Aug 22
425
Business combination disclosure
10 Aug 22
424B3
Prospectus supplement
29 Jul 22
S-4/A
Registration of securities issued in business combination transactions (amended)
26 Jul 22
425
Business combination disclosure
6 Jul 22
S-4
Registration of securities issued in business combination transactions
15 Jun 22
425
Business combination disclosure
9 Jun 22
425
Business combination disclosure
27 Apr 22
S-8
Registration of securities for employees
30 Jun 21
424B5
Prospectus supplement for primary offering
4 Jun 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
23 Apr 18
DEFA14A
Additional proxy soliciting materials
23 Apr 18
DEFA14A
Additional proxy soliciting materials
8 May 17
DEFA14A
Additional proxy soliciting materials
4 May 17
DEFA14A
Additional proxy soliciting materials
30 Apr 17
DEFA14A
Additional proxy soliciting materials
26 Apr 17
Other
EFFECT
Notice of effectiveness
29 Jul 22
EFFECT
Notice of effectiveness
5 May 21
CORRESP
Correspondence with SEC
29 Apr 21
UPLOAD
Letter from SEC
5 Apr 21
EFFECT
Notice of effectiveness
8 Feb 21
CORRESP
Correspondence with SEC
2 Feb 21
UPLOAD
Letter from SEC
2 Feb 21
EFFECT
Notice of effectiveness
28 Aug 20
CORRESP
Correspondence with SEC
24 Aug 20
UPLOAD
Letter from SEC
24 Aug 20
Ownership
SC 13G/A
CALADRIUS BIOSCIENCES / CVI Investments ownership change
14 Feb 22
SC 13G/A
CALADRIUS BIOSCIENCES / RENAISSANCE TECHNOLOGIES ownership change
10 Feb 22
SC 13G/A
CALADRIUS BIOSCIENCES / MMCAP International Inc. SPC ownership change
3 Feb 22
SC 13G/A
CALADRIUS BIOSCIENCES / Empery Asset Management ownership change
19 Jan 22
4
CALADRIUS BIOSCIENCES / David J Mazzo ownership change
18 Jan 22
4
CALADRIUS BIOSCIENCES / Todd C Girolamo ownership change
18 Jan 22
4
CALADRIUS BIOSCIENCES / David J Mazzo ownership change
12 Jan 22
4
CALADRIUS BIOSCIENCES / Todd C Girolamo ownership change
12 Jan 22
4
CALADRIUS BIOSCIENCES / Kristen K Buck ownership change
12 Jan 22
4
CALADRIUS BIOSCIENCES / Anne Clem Whitaker ownership change
12 Jan 22
Patents
Utility
Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection
27 Jan 22
The described invention provides a method for treating a subject at risk for a lung injury derived from a severe virus infection.
Utility
Stem Cell Compositions for Cosmetic and Dermatologic Use
21 Oct 20
Disclosed herein are cosmetic compositions containing stem cell secreted proteins that, in a cosmetic amount, are effective to enhance appearance of photo-damaged, or aged, skin.
Transcripts
2022 Q2
Earnings call transcript
5 Aug 22
2022 Q1
Earnings call transcript
6 May 22
2021 Q4
Earnings call transcript
23 Mar 22
2021 Q3
Earnings call transcript
4 Nov 21
2021 Q2
Earnings call transcript
6 Aug 21
2021 Q1
Earnings call transcript
7 May 21
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
13 Aug 20
2020 Q1
Earnings call transcript
7 May 20
Reddit threads
Daily Discussion Thread - August 3rd, 2022
3 Aug 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
🌞 #premarket #watchlist 04/27 $COSM -no news , $AFIB -Announces Agreements to Fund Strategic Growth Priorities , $BRQS -old news, $CLBS -Announce Definitive Merger Agreement, $XBIO -Expands Oncology Pipeline... Also check postmarket runners and low float stocks in Realtime Stock Screener!
27 Apr 22
Daily Discussion Thread - March 22nd, 2022
22 Mar 22
Daily Discussion Thread - March 17th, 2022
17 Mar 22
Daily Discussion Thread - March 16th, 2022
16 Mar 22
Daily Discussion Thread - March 15th, 2022
15 Mar 22
Daily Discussion Thread - March 14th, 2022
14 Mar 22
Daily Discussion Thread - March 10th, 2022
10 Mar 22